Update: Two clinical trials underway, 3 more in the wings
Prescient is developing two promising cancer compounds that target major tumour survival pathways. It has two Phase Ib/II trials underway, and plans to initiate three more over the next year. Recent positive results from Merck validate the mechanism of action of PTX-200, which targets Akt. Prescient requires additional funding to advance its drug development programme. Our valuation is A$36m, or A$0.62 per share (pre-funding).Prescient Therapeutics is a holding company. Through its subsidiaries, Co. is engaged in: the construction of vectors and biologic components, and the manufacture of biologic drugs for clinical trial purposes; the preparation for and conduct of clinical trials; business development associated with the promotion of its technologies; and business development associated with developing collaborative, partnership relationships and corporate transactions.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.